(Q80363848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

relapsing-remitting multiple sclerosis

1 reference

Pierluigi Russo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Alessandro Capone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Andrea Paolillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Francesco Macchia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Federica Ranzato

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Gianfranco Costantino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Luca Degli sposti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Luciano Caprino

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

409-420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis in Italy. A reappraisal of incidence and prevalence in Ferrara.

30 December 2019

cites work

1 reference

12 December 2020

Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group.

1 reference

12 December 2020

Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

1 reference

12 December 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

A cost-utility analysis of interferon beta for multiple sclerosis

1 reference

12 December 2020

The economics of multiple sclerosis. Distribution of costs and relationship to disease severity

1 reference

12 December 2020

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

1 reference

12 December 2020

Methods for comparison of cost data

1 reference

12 December 2020

The economic cost of multiple sclerosis in Sweden in 1994.

1 reference

12 December 2020

A comprehensive assessment of the cost of multiple sclerosis in the United States.

1 reference

12 December 2020

Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Economic consequences of multiple sclerosis for Canadians

1 reference

12 December 2020

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

1 reference

12 December 2020

Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Management of multiple sclerosis

1 reference

12 December 2020

The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

1 reference

12 December 2020

How should cost data in pragmatic randomised trials be analysed?

1 reference

12 December 2020

Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians

1 reference

12 December 2020

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

12 December 2020

An epidemiological study of multiple sclerosis in central Sardinia, Italy.

1 reference

12 December 2020

10.2165/00044011-200424070-00004

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17516727%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference